Physician profile
Paul M Chretien
NPI 1972615227
$3,791.19
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,681 · 2020: $111.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $1,197.14 | 2019-2020 | |
| Ucb, INC. | $533.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $389.02 | 2019 | |
| Supernus Pharmaceuticals, INC. | $305.16 | 2019-2020 | |
| Greenwich Biosciences, INC. | $299.83 | 2019 | |
| Sunovion Pharmaceuticals INC. | $233.48 | 2019 | |
| Neos Therapeutics, Lp | $173.08 | 2019 | |
| Ironshore Pharmaceuticals INC. | $130.02 | 2019 | |
| Livanova USA, INC. | $79.35 | 2019-2020 | |
| Eisai INC. | $78.31 | 2019 | |
| Mallinckrodt Enterprises LLC | $75.54 | 2019 | |
| Aquestive Therapeutics, INC. | $51.28 | 2019 | |
| Ptc Therapeutics, INC. | $41.98 | 2019 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $39.84 | 2019 | |
| Vertical Pharmaceuticals, LLC | $36.59 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $23.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.08 | 2019 | |
| Travere Therapeutics, INC. | $17.60 | 2019 | |
| Grifols USA, LLC | $17.50 | 2019 | |
| Biomarin Pharmaceutical INC. | $17.19 | 2019 | |
| Promius Pharma LLC | $16.42 | 2019 | |
| Allergan, INC. | $13.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Chretien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.